

# Estonia

## Recent and planned developments in pharmaceutical policies 2019

### Special topic: patient-based reimbursement decisions

#### CHANGES IN PRICING

No changes

#### CHANGES IN REIMBURSEMENT


First biological medicine (*adalimumab*) is reimbursed through the list of reimbursed medicinal products and is available in retail pharmacies (from 1st of July 2019), before that biological medicines were available only in hospitals and were reimbursed through the list of in-patient healthcare services.

Harmonizing amendment procedures for in and out-patient products reimbursement lists.

E.g. pharmacoeconomic evaluation of medicinal products for in-patient healthcare services list are made by marketing authorisation holders (before it was done by healthcare specialist) (beginning of 2019)

#### OTHER CHANGES

**Cross-border digital prescription:** possibility to buy medicines in Estonia that have been digitally prescribed in Finland since January 2019.



**Electronic information about patient's medicines** – an overview of patient's prescription medicines (prescribed, bought) → can be seen by the patient, pharmacist and physician (in progress, from 2019).



**Medicines with managed entry agreement (MEA) pilot project in e-prescription system** – MEA medications prescribed and dispensed through e-prescription system → better overview of the usage, better accountability, more accurate statistics, transparency, better observance of the conditions (in progress, 2019).



### SPECIAL TOPIC: patient-based reimbursement decisions

#### OUT-PATIENT

#### Special applications from patients and doctors to EHIF

(info about diagnosis, previous treatment, medical history, medicine name, medical arguments, alternatives, scientific publications, price etc)

Decisions are made by EHIF Medicinal Products and Medical Devices Department specialist:

**1. for medicines that can be used in home without any help of doctors, nurses or medical personnel:**

- a) medicine has **no marketing authorisation** in Estonia (*usage must be approved by SAM*)
- b) medicine is **included in the reimbursement list** but in **other indications**

**2. for special medical food for orphan diseases**

(*for directly controlling the disease*)

**3. for food supplements for rare congenital metabolic disorders**

Specialist will evaluate disease severity, treatment alternatives, scientific data, price etc. Decisions are made **within 30 days** and **must be approved by EHIF board**. Reimbursement rates are **90%** and **for orphan diseases 100%**. After EHIF board approval reimbursement rates and medicine info are entered in the e-prescription system and patient's **medicine is reimbursed throughout the treatment period**.

#### IN-PATIENT

There is no patient-based reimbursement decisions.